Allen S S, Hatsukami D, Jensen J, Grillo M, Bliss R
Department of Family Practice, University of Minnesota Medical School, Minneapolis 55455, USA.
Prev Med. 1995 Jul;24(4):357-62. doi: 10.1006/pmed.1995.1058.
Studies show sustained levels of nicotine among young males using smokeless tobacco, causing concern for subsequent cardiovascular risk. Also, there is little information on effects of nicotine replacement on cardiovascular risk in cessation programs. This study investigates the effects of nicotine gum replacement in smokeless tobacco cessation on cardiovascular risk factors.
Smokeless tobacco users, ages 18-65, were randomly assigned in a double-blind fashion to 2-mg nicotine or placebo gum. At baseline, Week 4, and Week 8, dependent measurements, heart rate, blood pressure, and weight were recorded, and fasting lipoprotein profiles were drawn.
This paper focuses on the smokeless tobacco users who refrained from use during the study period (N = 56). The nicotine gum group weighed less (P = 0.033) than the placebo group throughout the study and weight increased at a significant rate between Weeks 4 and 8 for both groups as gum decreased. Triglycerides were higher for the nicotine gum group than the placebo group (P = 0.031), with triglycerides decreasing between Weeks 4 and 8, with a similar effect seen among nonabstinent smokeless tobacco users. There was no dose, time, or dose by time effect for the other dependent measures.
Among smokeless tobacco users who were abstinent, weight increased, with subjects on nicotine gum weighing less throughout the study. The lipoprotein profile, heart rate, and blood pressure did not improve over time, contrary to smokers in whom HDL increases and heart rate decreases with cessation. This could relate to different routes of administration, pharmacokinetics, or by-products of tobacco smoking being absent in smokeless tobacco. In addition, nicotine gum appeared to have neither an adverse nor a positive effect on heart rate, blood pressure, LDL, HDL, or total cholesterol.
研究表明,使用无烟烟草的年轻男性体内尼古丁水平持续存在,这引发了人们对其后续心血管风险的担忧。此外,关于尼古丁替代疗法对戒烟项目中心血管风险的影响,相关信息较少。本研究调查了尼古丁口香糖替代疗法在无烟烟草戒烟中对心血管危险因素的影响。
年龄在18 - 65岁的无烟烟草使用者以双盲方式随机分配至2毫克尼古丁口香糖组或安慰剂口香糖组。在基线、第4周和第8周时,记录心率、血压和体重等相关测量值,并采集空腹脂蛋白谱。
本文重点关注在研究期间戒除使用无烟烟草的使用者(N = 56)。在整个研究过程中,尼古丁口香糖组的体重低于安慰剂组(P = 0.033),并且随着口香糖使用量减少,两组在第4周和第8周之间体重均显著增加。尼古丁口香糖组的甘油三酯水平高于安慰剂组(P = 0.031),甘油三酯在第4周和第8周之间下降,在未戒除无烟烟草的使用者中也观察到类似效果。其他相关测量指标不存在剂量、时间或剂量与时间的交互作用。
在戒除无烟烟草的使用者中,体重增加,在整个研究过程中使用尼古丁口香糖的受试者体重较轻。脂蛋白谱、心率和血压并未随时间改善,这与吸烟者不同,吸烟者戒烟后高密度脂蛋白增加且心率下降。这可能与给药途径、药代动力学不同或无烟烟草中不存在吸烟的副产物有关。此外,尼古丁口香糖似乎对心率、血压、低密度脂蛋白、高密度脂蛋白或总胆固醇既无不良影响也无积极影响。